Skip to main content

Table 3 Predictors of Original Site Failure

From: Optimal timing and clinical value of radiotherapy in advanced ALK-rearranged non-small cell lung cancer with or without baseline brain metastases: implications from pattern of failure analyses

  Univariate Analysis Multivariate Analysis
SHR p SHR p
Age (≤50y vs >50y) 0.55 (0.26–1.16) 0.116   
Sex (female vs male) 0.61 (0.29–1.26) 0.183   
Histology (non-adenocarcinoma vs adenocarcinoma) 0.19 (0.08–0.43) < 0.001 0.19 (0.05–0.78) 0.021
ECOG (0–1 vs 2) 0.45 (0.12–1.75) 0.250   
Primary tumor size (< 3.5 vs ≥3.5) 2.74 (1.28–5.87) 0.010 2.45 (1.12–5.35) 0.024
T stage (T1–2 vs T3–4) 0.88 (0.42–1.85) 0.749   
N stage (N0 vs N1–3) 3.13 (0.68–14.5) 0.144   
Number of metastatic organs (1–2 vs ≥3) 2.44 (1.14–5.24) 0.022 1.77 (0.78–4.04) 0.175
Number of metastatic lesions (1–5 vs ≥6) 4.16 (1.29–13.5) 0.017 3.12 (0.77–12.7) 0.111
Presence of lung metastases (No vs Yes) 0.84 (0.33–2.10) 0.703   
Presence of liver metastases (No vs Yes) 1.57 (0.06–4.39) 0.386   
Presence of brain metastases (No vs Yes) 3.50 (1.62–7.54) 0.001 2.31 (1.07–4.97) 0.033
Presence of adrenal metastases (No vs Yes) 1.59 (0.51–4.95) 0.423   
Presence of bone metastases (No vs Yes) 1.13 (0.51–2.37) 0.737   
Prior lines of therapy (≥1 vs 0) 1.02 (0.48–2.10) 0.960   
Prior local therapy (No vs Yes) 1.13 (0.55–2.32) 0.731   
Objective response (No or Yes) 0.84 (0.36–1.95) 0.691   
  1. ECOG Eastern Cooperative Oncology Group